BR112014007469A2 - arcabouços de proteína com base em repetição de fibronectina tipo iii com superfícies de ligação alternativas - Google Patents

arcabouços de proteína com base em repetição de fibronectina tipo iii com superfícies de ligação alternativas

Info

Publication number
BR112014007469A2
BR112014007469A2 BR112014007469A BR112014007469A BR112014007469A2 BR 112014007469 A2 BR112014007469 A2 BR 112014007469A2 BR 112014007469 A BR112014007469 A BR 112014007469A BR 112014007469 A BR112014007469 A BR 112014007469A BR 112014007469 A2 BR112014007469 A2 BR 112014007469A2
Authority
BR
Brazil
Prior art keywords
type iii
alternative binding
iii fibronectin
binding surfaces
fibronectin repeat
Prior art date
Application number
BR112014007469A
Other languages
English (en)
Other versions
BR112014007469B1 (pt
Inventor
Diem Michael
Jacobs Steven
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of BR112014007469A2 publication Critical patent/BR112014007469A2/pt
Publication of BR112014007469B1 publication Critical patent/BR112014007469B1/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1044—Preparation or screening of libraries displayed on scaffold proteins
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]

Abstract

resumo patente de invenção: "arcabouços de proteína com base em repetição de fibronectina tipo iii com superfícies de ligação alternativas". a presente invenção refere-se a arcabouços de proteína e a bibliotecas de arcabouços com base em uma repetição de fibronectina tipo iii (fn3) com um modelo de superfície de ligação alternativo, ácidos nucleicos isolados que codificam os arcabouços de proteína, vetores, células hospedeiras e métodos de produção dos mesmos que são úteis na geração de moléculas terapêuticas e tratamento e diagnóstico de doenças e distúrbios.
BR112014007469-0A 2011-09-27 2012-09-27 Método de fabricação de uma biblioteca de domínios de módulo de fibronectina tipo iii (fn3), biblioteca e método para obter um arcabouço de proteína BR112014007469B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161539670P 2011-09-27 2011-09-27
US61/539,670 2011-09-27
PCT/US2012/057436 WO2013049275A1 (en) 2011-09-27 2012-09-27 Fibronectin type iii repeat based protein scaffolds with alternative binding surfaces

Publications (2)

Publication Number Publication Date
BR112014007469A2 true BR112014007469A2 (pt) 2017-04-04
BR112014007469B1 BR112014007469B1 (pt) 2022-06-14

Family

ID=47911927

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014007469-0A BR112014007469B1 (pt) 2011-09-27 2012-09-27 Método de fabricação de uma biblioteca de domínios de módulo de fibronectina tipo iii (fn3), biblioteca e método para obter um arcabouço de proteína

Country Status (13)

Country Link
US (3) US9200273B2 (pt)
EP (3) EP4151785A1 (pt)
JP (3) JP6440496B2 (pt)
KR (2) KR102142385B1 (pt)
CN (2) CN103827361A (pt)
AU (2) AU2016269407A1 (pt)
BR (1) BR112014007469B1 (pt)
CA (1) CA2849774C (pt)
EA (1) EA035150B1 (pt)
ES (1) ES2928578T3 (pt)
IL (3) IL277891B2 (pt)
MX (1) MX358827B (pt)
WO (1) WO2013049275A1 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2402567C2 (ru) 2003-12-05 2010-10-27 Бристоль-Майерз Сквибб Компани Ингибиторы рецепторов фактора роста эндотелия сосудов типа 2
EP3156415A1 (en) 2006-11-22 2017-04-19 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
KR20100128291A (ko) 2008-02-14 2010-12-07 브리스톨-마이어스 스큅 컴퍼니 Ｅｇｆｒ에 결합하는 조작된 단백질을 기초로 하는 표적화된 치료제
JP2011520961A (ja) 2008-05-22 2011-07-21 ブリストル−マイヤーズ スクイブ カンパニー 多価フィブロネクチンをベースとする足場ドメインタンパク質
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
EP2576615B1 (en) 2010-05-26 2016-03-30 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
ES2876421T3 (es) 2011-04-13 2021-11-12 Bristol Myers Squibb Co Proteínas de fusión Fc que comprenden enlazadores o disposiciones nuevos
US20140187488A1 (en) 2011-05-17 2014-07-03 Bristol-Myers Squibb Company Methods for maintaining pegylation of polypeptides
CN104053670A (zh) 2011-10-31 2014-09-17 百时美施贵宝公司 具有降低的免疫原性的纤连蛋白结合域
LT2895503T (lt) 2012-09-13 2019-07-25 Bristol-Myers Squibb Company Karkasiniai domeniniai baltymai fibronektino pagrindu, kurie sąveikauja su miostatinu
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
US20150361159A1 (en) 2013-02-01 2015-12-17 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
EP2953968B1 (en) 2013-02-06 2018-07-25 Bristol-Myers Squibb Company Fibronectin type iii domain proteins with enhanced solubility
EP3617220B1 (en) 2013-02-12 2021-03-24 Bristol-Myers Squibb Company High ph protein refolding methods
JP2017502002A (ja) * 2013-12-09 2017-01-19 ニューヨーク・ユニバーシティ 抗ブドウ球菌剤の食細胞送達用組成物及び方法
US10442851B2 (en) 2014-03-20 2019-10-15 Bristol-Myers Squibb Company Serum albumin-binding fibronectin type III domains
US20170210788A1 (en) 2014-07-23 2017-07-27 Modernatx, Inc. Modified polynucleotides for the production of intrabodies
EP3224753B1 (en) * 2014-11-26 2024-04-10 Biolojic Design Ltd. Computer assisted antibody re-epitoping
KR20170138558A (ko) 2015-04-24 2017-12-15 비브 헬스케어 유케이 (넘버5) 리미티드 Hiv 융합을 표적으로 하는 폴리펩티드
EA201792441A2 (ru) * 2015-05-06 2018-06-29 Янссен Байотек, Инк. Домены фибронектина типа iii, связывающиеся с простатспецифическим мембранным антигеном
MA42059A (fr) 2015-05-06 2018-03-14 Janssen Biotech Inc Agents de liaison bispécifique à l'antigène membranaire spécifique de la prostate (psma) et utilisations de ceux-ci
JP6893504B2 (ja) 2015-09-23 2021-06-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 速い解離速度を有する血清アルブミン結合フィブロネクチンタイプｉｉｉドメイン
CN109562146A (zh) * 2016-06-03 2019-04-02 詹森生物科技公司 血清白蛋白结合纤连蛋白iii型结构域
RU2019104075A (ru) * 2016-07-15 2020-08-17 Посейда Терапьютикс, Инк. Химерные рецепторы антигенов (car), специфические для muc1, и способы их применения
US20190177421A1 (en) * 2016-07-15 2019-06-13 Poseida Therapeutics, Inc. Chimeric antigen receptors and methods for use
CA3036972A1 (en) * 2016-09-14 2018-03-22 Janssen Biotech, Inc. Chimeric antigen receptors comprising bcma-specific fibronectin type iii domains and uses thereof
US10611823B2 (en) 2016-12-14 2020-04-07 Hanssen Biotech, Inc CD137 binding fibronectin type III domains
US10597438B2 (en) * 2016-12-14 2020-03-24 Janssen Biotech, Inc. PD-L1 binding fibronectin type III domains
AU2017378226A1 (en) 2016-12-14 2019-06-20 Janssen Biotech, Inc. CD8A-binding fibronectin type III domains
CA3074317A1 (en) * 2017-08-25 2019-02-28 Janssen Biotech, Inc. Fc.gamma.rii binding fibronectin type iii domains, their conjugates and multispecific molecules comprising them
CN111727256A (zh) * 2017-09-08 2020-09-29 波赛达治疗公司 用于嵌合配体受体（clr）-介导的条件性基因表达的组合物和方法
SG11202003864XA (en) * 2017-12-13 2020-07-29 Janssen Biotech Inc Immortalized car-t cells genetically modified to eliminate t-cell receptor and beta 2-microglobulin expression
JP6936276B2 (ja) 2019-04-23 2021-09-15 矢崎総業株式会社 車両用アンテナ
KR20220034206A (ko) 2019-07-12 2022-03-17 얀센 파마슈티카 엔.브이. 결합제 및 이의 용도
US11628222B2 (en) 2019-10-14 2023-04-18 Aro Biotherapeutics Company CD71 binding fibronectin type III domains
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
WO2023249940A2 (en) * 2022-06-20 2023-12-28 Protelica, Inc. Fibronectin libraries for human therapeutic screening

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6018030A (en) 1986-11-04 2000-01-25 Protein Polymer Technologies, Inc. Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
ATE168416T1 (de) 1989-10-05 1998-08-15 Optein Inc Zellfreie synthese und isolierung von genen und polypeptiden
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
ATE275198T1 (de) 1991-12-02 2004-09-15 Medical Res Council Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken.
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
US6673901B2 (en) 1997-06-12 2004-01-06 Research Corporation Technologies, Inc. Artificial antibody polypeptides
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
EP1538206B1 (en) 1997-09-16 2010-03-24 Centocor, Inc. Method for the complete chemical synthesis and assembly of genes and genomes
US6846655B1 (en) 1998-06-29 2005-01-25 Phylos, Inc. Methods for generating highly diverse libraries
DE69941267D1 (de) 1998-12-10 2009-09-24 Bristol Myers Squibb Co Proteingerüste für antikörper-nachahmer und andere bindende proteine
US7115396B2 (en) * 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6472147B1 (en) 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
WO2002032925A2 (en) 2000-10-16 2002-04-25 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
GB0119476D0 (en) 2001-08-09 2001-10-03 Novartis Forschungsstiftlung Z Anti-tumour agents and method of identifying anti-tumour agents
JP4602614B2 (ja) 2001-09-26 2010-12-22 アイシン精機株式会社 自動車用ドア
AU2003243436A1 (en) 2002-06-06 2003-12-22 Shohei Koide Reconstituted polypeptides
AU2003260786B2 (en) 2002-09-06 2008-03-13 Isogenica Limited In vitro peptide expression libraray
WO2004029224A2 (en) 2002-09-30 2004-04-08 Compound Therapeutics, Inc. Methods of engineering spatially conserved motifs in polypeptides
CA2511910A1 (en) 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
RU2402567C2 (ru) 2003-12-05 2010-10-27 Бристоль-Майерз Сквибб Компани Ингибиторы рецепторов фактора роста эндотелия сосудов типа 2
US20080220049A1 (en) 2003-12-05 2008-09-11 Adnexus, A Bristol-Myers Squibb R&D Company Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
US20060040278A1 (en) 2004-01-27 2006-02-23 Cojocaru Gad S Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of ovarian cancer
TW200804593A (en) 2006-01-24 2008-01-16 Domantis Ltd Fusion proteins that contain natural junctions
SG134283A1 (en) 2006-01-24 2007-08-29 Ind Tech Res Inst Biomarkers for liver fibrotic injury
WO2008079973A2 (en) 2006-12-21 2008-07-03 Centocor, Inc. Egfr binding peptides and uses thereof
WO2008156642A1 (en) 2007-06-15 2008-12-24 Vasgene Therapeutics, Inc. Non-immunoglobulin antigen binding scaffolds for inhibiting angiogenesis and tumor growth
AU2008287426B2 (en) 2007-08-10 2014-06-26 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US8470966B2 (en) * 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
KR101686247B1 (ko) 2007-10-31 2016-12-14 메디뮨 엘엘씨 단백질 스캐폴드
WO2009086116A2 (en) 2007-12-19 2009-07-09 Centocor, Inc. Alternative scaffold protein fusions phage display via fusion to plx of m13 phage
JP2011507519A (ja) 2007-12-19 2011-03-10 セントコア・オーソ・バイオテツク・インコーポレーテツド ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法
JP2011507521A (ja) 2007-12-19 2011-03-10 セントコア・オーソ・バイオテツク・インコーポレーテツド ヒト非抗体ペプチド又はタンパク質ファージライブラリ
EP2383292A1 (en) * 2008-05-02 2011-11-02 Novartis AG Improved fibronectin-based binding molecules and uses thereof
US8394924B2 (en) * 2008-10-23 2013-03-12 Massachusetts Institute Of Technology Directed engagement of activating Fc receptors
BRPI0919881B1 (pt) * 2008-10-31 2021-09-08 Centocor Ortho Biotech Inc Proteína de arcabouço e seu método de geração, biblioteca e seu método de construção, molécula de ácido nucleico, vetor de ácido nucleico, célula hospedeira, composição, dispositivo médico e artigo de fabricação
US8415291B2 (en) * 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
EP2396011B1 (en) 2009-02-12 2016-04-13 Janssen Biotech, Inc. Fibronectin type iii domain based scaffold compositions, methods and uses
CN102472649A (zh) 2009-07-07 2012-05-23 西门子公司 用于测量多相流体流的设备和方法
ES2923567T3 (es) 2010-04-30 2022-09-28 Janssen Biotech Inc Composiciones del dominio de fibronectina estabilizadas, métodos y usos
CN107903321A (zh) 2010-07-30 2018-04-13 诺华有限公司 纤连蛋白摇篮分子和其库

Also Published As

Publication number Publication date
IL277891A (en) 2020-11-30
MX358827B (es) 2018-09-05
CA2849774A1 (en) 2013-04-04
EP4151785A1 (en) 2023-03-22
US20180143203A1 (en) 2018-05-24
CA2849774C (en) 2020-01-07
JP6445600B2 (ja) 2018-12-26
EA035150B1 (ru) 2020-05-06
KR102035713B1 (ko) 2019-10-24
EP2761066A4 (en) 2015-06-17
JP2017121238A (ja) 2017-07-13
EP3540100B1 (en) 2022-08-17
JP6440496B2 (ja) 2018-12-19
IL231585B (en) 2019-09-26
EP2761066B1 (en) 2018-12-05
KR20140069226A (ko) 2014-06-09
EP2761066A1 (en) 2014-08-06
CN110725009B (zh) 2024-01-30
KR20190121412A (ko) 2019-10-25
IL231585A0 (en) 2014-05-28
ES2928578T3 (es) 2022-11-21
MX2014003744A (es) 2014-08-22
AU2018204514B2 (en) 2020-06-18
JP2019081760A (ja) 2019-05-30
CN103827361A (zh) 2014-05-28
JP2014530014A (ja) 2014-11-17
AU2012316080A1 (en) 2014-04-03
WO2013049275A1 (en) 2013-04-04
AU2012316080B2 (en) 2016-09-01
CN110725009A (zh) 2020-01-24
IL269470A (en) 2019-11-28
US20160041182A1 (en) 2016-02-11
AU2012316080A8 (en) 2016-09-08
IL277891B1 (en) 2023-09-01
AU2016269407A1 (en) 2016-12-22
KR102142385B1 (ko) 2020-08-10
US9897612B2 (en) 2018-02-20
EA201490703A1 (ru) 2014-09-30
IL277891B2 (en) 2024-01-01
US9200273B2 (en) 2015-12-01
JP6722263B2 (ja) 2020-07-15
EP3540100A1 (en) 2019-09-18
US10571472B2 (en) 2020-02-25
BR112014007469B1 (pt) 2022-06-14
AU2018204514A1 (en) 2018-07-12
EP3540100B8 (en) 2022-11-02
US20130079243A1 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
BR112014007469A2 (pt) arcabouços de proteína com base em repetição de fibronectina tipo iii com superfícies de ligação alternativas
PH12019500694A1 (en) Factor viii compositions and methods of making and using the same
BR112014023898A2 (pt) moléculas de ácido nucleico artificiais compreendendo 5''utr top
MX2009002816A (es) Proteinas de fusion de albumina.
BR112019006384A2 (pt) enzimas modificadoras de ácido nucleico guiadas por rna e métodos de uso das mesmas
CY1118588T1 (el) Νεα 5-αμινοτετραϋδροκινολινο-2-καρβοξυλικα οξεα και η χρηση τους
BR112016020688A2 (pt) Composições úteis no tratamento da deficiência da ornitina transcarbamilase (otc)
BR112015010318A2 (pt) Variantes de albumina
BRPI0614761A2 (pt) proteìnas de fusão de albumina
AR076541A1 (es) Mutantes de fgf21 y usos del mismo
BR112014018916A2 (pt) classe de genes de resistência a glifosato
FI3581650T3 (fi) IX-tekijän polypeptidimutantti, sen käyttöjä ja menetelmä sen valmistamiseksi
EA201170635A1 (ru) Композиции, способы получения и применение каркаса на основе домена фибронектина типа iii
BR112012033699A2 (pt) polipeptídeo tendo atividade beta-glicosidase e seus usos
EA201590488A1 (ru) Способы модификации клеток-хозяев
EA201270713A1 (ru) Белки на основе фибронектина с каркасными доменами, которые связывают ил-23
EA202091568A1 (ru) Ингибиторы глюкозилцерамид-синтазы
BR112012033703A2 (pt) polipeptídeo tendo atividade beta-glicosidase e seus usos
EA201100225A1 (ru) Новые регуляторные элементы
EA201590910A1 (ru) Белки на основе структурного домена фибронектина, связывающие pcsk9
MY177065A (en) 4-1bb binding molecules
BR112012006501A8 (pt) Polipeptídios e usos dos mesmos
BR112012028805A2 (pt) composições de endorribonuclease e métodos de uso das mesmas.
BR112017020961A2 (pt) muteína, molécula de ácido nucleico, célula hospedeira, método de produção de uma muteína e método de ligação
BR112014026531A2 (pt) proteínas de ligação de antígeno ligando cd30 humano

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/09/2012, OBSERVADAS AS CONDICOES LEGAIS